SCHEMBL30121609

SCHEMBL30121609

CC(C)(C)OC(=O)N[C@H]1CCc2ccc(Nc3nc(N)n(-c4cc5c(nn4)-c4ccccc4CCC5)n3)cc2CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 12/20 0.67
FLT3 P36888 2/20 0.67
AURKA O14965 1/20 0.67
EGFR P00533 1/20 0.67
RET P07949 1/20 0.67
MET P08581 1/20 0.67
KIT P10721 1/20 0.67
SRC P12931 1/20 0.67
PDGFRA P16234 1/20 0.67
KDR P35968 1/20 0.67
TYRO3 Q06418 1/20 0.67
DDR1 Q08345 1/20 0.67
MERTK Q12866 1/20 0.67
AURKB Q96GD4 1/20 0.67
ALK Q9UM73 1/20 0.67
JAK2 O60674 3/20 0.38
JAK3 P52333 3/20 0.38
PTK2 Q05397 3/20 0.38
DRD2 P14416 2/20 0.38
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2056607 1.00 AXL (0.67) AXLFLT3AURKAEGFRRET
SCHEMBL2056661 0.92 AXL (0.56) AXLFLT3AURKAEGFRRET
SCHEMBL30090826 0.92 AXL (0.56) AXLFLT3AURKAEGFRRET
SCHEMBL467955 0.90 AXL (0.72) AXLFLT3AURKAEGFRRET
SCHEMBL30090777 0.90 AXL (0.72) AXLFLT3AURKAEGFRRET
SCHEMBL2056491 0.89 AXL (0.51) AXLFLT3AURKAEGFRRET
SCHEMBL30090801 0.89 AXL (0.51) AXLFLT3AURKAEGFRRET
SCHEMBL1639234 0.89 AXL (0.68) AXLFLT3AURKAEGFRRET
SCHEMBL30090776 0.89 AXL (0.68) AXLFLT3AURKAEGFRRET
SCHEMBL12670653 0.86 AXL (0.78) AXLFLT3AURKAEGFRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4125908-A1 COMBINATION THERAPY COMPRISING AN AXL INHIBITOR BerGenBio ASA (NO) 2023-02-08 EP claimed
EP-4138823-A1 METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR BerGenBio ASA (NO) 2023-03-01 EP disclosed
EP-4125908-A1 COMBINATION THERAPY COMPRISING AN AXL INHIBITOR BerGenBio ASA (NO) 2023-02-08 EP disclosed